TACR3 tachykinin receptor 3
ENSG00000169836 · protein coding · Open Targets profile
Receptor for the tachykinin neuromedin-K (neurokinin B), also able to bind and respond to tachynins substance K/neurokinin A and substance P (PubMed:1312036, PubMed:37391393). The rank order of affinity of this receptor to tachykinins is: neuromedin-K > substance K and substance P (PubMed:1312036). Neuromedin-K binding to its receptor triggers G protein-coupled receptor signaling via activation of G(q) and phosphatidylinositol hydrolysis by phospholipase C (PubMed:37391393). Neuromedin-K binding also triggers signaling via activation of adenylate cyclase activity which results in increased intracellular levels of cyclic AMP (cAMP) (By similarity). {ECO:0000250|UniProtKB:P16177, ECO:0000269|PubMed:1312036, ECO:0000269|PubMed:37391393}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, High-Quality Ligand, Druggable Family
- Antibody
- GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
- PROTAC
- Small Molecule Binder
gnomAD loss of function constraint: o/e 0.9728299975395203 (upper bound 1.295199990272522). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 39 registry trials, updated in the last three years, of the most advanced drugs against TACR3 (elinzanetant, fezolinetant, talnetant, pavinetant), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Chi Fai NGChinese University of Hong Kong · 1 of 1 trials Phase 2+
- Emily LauMassachusetts General Hospital · 1 of 1 trials Phase 2+
- Maryam LustbergYale University · 1 of 1 trials Phase 2+
- Nanette SantoroUniversity of Colorado, Denver · 1 of 1 trials Phase 2+
- Norah L HenryUniversity of Michigan Rogel Cancer Center · 1 of 1 trials Phase 2+
- Rebecca C ThurstonUniversity of Pittsburgh · 1 of 1 trials Phase 2+
- Shehzad S BasariaBrigham and Women's Hospital · 1 of 1 trials Phase 2+
Registry trials of elinzanetant, fezolinetant, talnetant, pavinetant updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 27 of 38 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 1 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
1 trials of drugs against TACR3 were stopped early
Terminated, withdrawn and suspended interventional trials of elinzanetant, fezolinetant, talnetant, pavinetant, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 1 most recent of 1.
- terminated · 2026-05-06 · University of Michigan Rogel Cancer Center · Fezolinetant“Lack of Patient Interest”
Paediatric incentives and obligations for TACR3's drugs
For elinzanetant, fezolinetant, talnetant, pavinetant: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · TACR3 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-003500-PIP01-23 (elinzanetant, Treatment of vasomotor symptoms caused by endocrine therapy related to breast cancer): W: decision granting a waiver in all age groups for all conditions or indications, 29 Dec 2023Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA EMEA-003500-PIP01-23, 2026-11-11
- EU orphan designation: no · No EU orphan designation names elinzanetant, fezolinetant, talnetant, pavinetantRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Lynkuet: authorised since 17 Nov 2025; Veoza: authorised since 7 Dec 2023Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of elinzanetant, fezolinetant, talnetant, pavinetantRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: no · No interventional study of elinzanetant, fezolinetant, talnetant, pavinetant includes patients under 18Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 4 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.
| Drug | Type | Highest stage | Indications | Source records |
|---|---|---|---|---|
| ELINZANETANT | Small molecule | approval | breast neoplasm, menopause, Hot flashes, Sleep disturbance, opiate dependence | Open Targets · ChEMBL |
| FEZOLINETANT | Small molecule | approval | menopause, Hot flashes | Open Targets · ChEMBL |
| TALNETANT | Small molecule | phase 2 | irritable bowel syndrome, schizoaffective disorder, schizophrenia | Open Targets · ChEMBL |
| PAVINETANT | Small molecule | phase 2 | multiple sclerosis symptom measurement, schizophrenia, polycystic ovary syndrome | Open Targets · ChEMBL |